The who has called “encouraging” the drug against coronavirus

Encouraging results against COVID-19 for testing antiviral drugs showed that while only “Ramdevpir,” said chief researcher who Sumia Swaminathan.

“At the moment, apart from “Ramdevpir”, which showed itself in reducing hospitalizations, but not mortality, there is no other promising antiviral drugs,” she said at the briefing the foreign correspondents Association in Geneva office of the United Nations.

Two days earlier, Swaminathan said that the test of “Ramdevpir” still ongoing, its effectiveness in the fight against COVID-19 has not yet been confirmed.

“What we know today, it is published in China, which did not show any benefit from “Ramdevpir”, as well as the publication of the National Institute of health, USA, which indicate a reduction of 30% of the time hospitalization is infected. We know that “Ramdevpir” antiviral medicine, but we don’t know about efficiency,” she said.

The Drug “Ramdevpir”

“Ramdevpir” was urgently approved may 1 in the U.S. for the treatment COVID-19. At the time it was developed in the framework of the fight against Ebola, but not managed to prove its effectiveness.

The British newspaper the Guardian reported this week that the United States bought about 90% of three month supply “of Ramdevpir” from the California biopharmaceutical company Gilead Sciences, thus, UK and European countries have limited access to medication. The first 140 thousand doses of the drug were sold worldwide.

In late June, the U. S. bought about 500 thousand doses, which is about 90% of the stock of the drug for three months. Thus, States have significantly limited the access of other countries to the medication, experts say.

What medications from COVID-19 are used in Russia

In late may, “Aviewer” proven at the end of a clinical trial, received a registration certificate of Ministry of health and became the world’s first drug against COVID-19 containing the active substance, favipiravir. Later it was included in the list of methodological recommendations for the prevention, diagnosis and treatment coronavirus infection.

Joint venture, FUND and Ledger Chemrar increased production capacity three times, and now we can produce up to 300 thousand courses of the drug per month. This is expected to allow meeting the domestic demand for “Aviewer” and begin its deliveries abroad. Only in June, has made 100 thousand courses of the drug — almost twice Perepyolkin plan.